US 12,252,544 B2
Anti-CD63 antibodies, conjugates, and uses thereof
Katherine Cygnar, New York, NY (US); Andrew Baik, Bronx, NY (US); Christopher Schoenherr, Piermont, NY (US); and Andrew J. Murphy, Croton-on-Hudson, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Appl. No. 17/056,301
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
PCT Filed May 17, 2019, PCT No. PCT/US2019/032922
§ 371(c)(1), (2) Date Nov. 17, 2020,
PCT Pub. No. WO2019/222663, PCT Pub. Date Nov. 21, 2019.
Claims priority of provisional application 62/777,592, filed on Dec. 10, 2018.
Claims priority of provisional application 62/681,563, filed on Jun. 6, 2018.
Claims priority of provisional application 62/673,098, filed on May 17, 2018.
Prior Publication US 2021/0079109 A1, Mar. 18, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 48/00 (2006.01); C12N 9/34 (2006.01)
CPC C07K 16/2896 (2013.01) [C12N 9/2428 (2013.01); A61K 2039/505 (2013.01); A61K 48/00 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01)] 24 Claims
 
1. An anti-CD63 antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDRs) within the heavy chain variable region (HCVR) amino acid sequence and three light chain complementarity determining regions (LCDRs) within the light chain variable region (LCVR) amino acid sequence of an HCVR/LCVR pair selected from the group consisting of SEQ ID NOs: 2/10, SEQ ID NOs: 18/26, SEQ ID NOs: 34/42, SEQ ID NOs: 50/58, SEQ ID NOs: 66/74, SEQ ID NOs: 82/90, SEQ ID NOs: 98/106, SEQ ID NOs: 114/122, SEQ ID NOs: 130/138, SEQ ID NOs: 146/154, SEQ ID NOs: 162/170, SEQ ID NOs: 178/186, SEQ ID NOs: 194/202, SEQ ID NOs: 210/218, SEQ ID NOs: 226/234, SEQ ID NOs: 242/250, SEQ ID NOs: 258/266, SEQ ID NOs: 274/282, SEQ ID NOs: 290/282, SEQ ID NOs: 298/282, SEQ ID NOs: 306/282, SEQ ID NOs: 314/282, SEQ ID NOs: 322/282, and SEQ ID NOs: 330/282.